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Traumatic brain injuryMethamphetamine is a psychostimulant that was initially synthesized in 1920. Since then it has been used to
treat attention deﬁcit hyperactive disorder (ADHD), obesity and narcolepsy. However, methamphetamine has
also become a major drug of abuse worldwide. Under conditions of abuse, which involve the administration of
high repetitive doses,methamphetamine can produce considerable neurotoxic effects. However, recent evidence
from our laboratory indicates that low doses of methamphetamine can produce robust neuroprotection when
administeredwithin 12 h after severe traumatic brain injury (TBI) in rodents. Thus, it appears that methamphet-
amine under certain circumstances and correct dosing can produce a neuroprotective effect. This review
addresses the neuroprotective potential ofmethamphetamine and focuses on the potential beneﬁcial application
for TBI.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Methamphetamine has become a major drug of abuse worldwide.
There is clear evidence that when ingested at high repetitive doses,
methamphetamine produces measurable neurotoxicity (Ares-Santos
et al., 2013; Ares-Santos et al., 2014; Cadet and Krasnova, 2009;
Krasnova and Cadet, 2009). While there is considerable evidence that
methamphetamine abuse produces detrimental CNS alterations,
there is contrasting evidence that methamphetamine can produce
neuroprotective effects. In a 2008 study, O'Phelan et al. reported that
severe traumatic brain injury (TBI) patients that tested positive forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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unexplained, decrease in mortality (odds ratio of 0.25 (p = 0.02))
(O'Phelan et al., 2008). In their discussion, the authors raised the
point that methamphetamine may have both neurotoxic and neuro-
protective capabilities. Interestingly, in a second study, O'Phelan
et al. (2013) reported that TBI patients who tested positive for
methamphetamine exhibited a signiﬁcant (60%) reduction in
pericontusional cerebral blood ﬂow. These observations suggest that
methamphetamine presents an interesting paradox of neuroprotec-
tion and neurotoxicity.
In the United States, 1.7 million individuals suffer from TBI every
year. TBI represents a leading cause of disability worldwide. The annual
costs of TBI have been estimated at $60 billion. Clearly there is a crucial
unmet need to develop novel, effective therapies that can be adminis-
tered within a clinically relevant therapeutic window following injury.
Unfortunately, there are currently no approved therapeutic interven-
tions available to prevent cognitive and behavioral deﬁcits following
TBI. However, our laboratory and others have begun examining the
potential therapeutic beneﬁts of methamphetamine. In this review we
will highlight the potential mechanisms of neuroprotection activated
by the controlled administration of low dose methamphetamine.
2. Preclinical studies
There has been a small but growing body of research supporting the
use of amphetamines for the treatment of brain injury. Beginning in the
early 1980's Hovda and Fenney performed studies inwhich a small dose
(5 mg/kg) of amphetamine was administered during the chronic phase
of injury to cats with motor cortex damage. They observed a signiﬁcant
reduction in motor deﬁcits that was blocked by haloperidol, a preferen-
tial D2 type antagonist (Feeney and Hovda, 1983; Hovda and Feeney,
1985). Hovda and Fenney went on to show that D-amphetamine, admin-
istered 10 days after frontal cortex damage in a cat, produced a signiﬁcant,
long-term improvement in motor cortex associated tasks (Hovda and
Fenney, 1984; Hovda et al., 1989). Following these studies, Dhillon et al.
(1998) demonstrated that amphetamine administration after TBI in rats
reduced lactate levels as well as palmitic, stearic, oleic and arachidonic
acids that typically lead to inﬂammation. In support of these ﬁndings,
we recently reported that treatment with low dose methamphetamine
(IV infusion with 0.5 mg/kg/h for 24 h) after severe TBI signiﬁcantly
reduced pro-inﬂammatory signals, which also correlated with signiﬁcant
improvements in functional and cognitive performance (Rau et al., 2014).
Researchers have also demonstrated that amphetamine treatment
increased both brain derived neurotrophic factor (BDNF) and synapsin I
after a cortical contusion in rats, further suggesting potential neuroprotec-
tive effects for amphetamines (Griesbach et al., 2008).
3. Clinical studies
Based on these previous studies, one may conclude that amphet-
amines have signiﬁcant potential as treatment for acute brain injury.
However, the number of clinical trials that have utilized amphetamines
is limited.Walker-Batson et al. (1995) found that 10 stroke patients that
were given 10 mg of D-amphetamine every fourth day for 10 sessions
and paired with physical therapy had a signiﬁcant improvement in
motor function compared to placebo treated controls. This effect was
present up to one year even after amphetamine administration was
discontinued. While this early study is encouraging, other subsequent
small stroke trials have not been as successful. A recent review analyzed
ten clinical trials conducted on stroke patients using D-amphetamine
and found that only two reported a signiﬁcant improvement in neuro-
logical outcomes (Harbeck-Seu et al., 2011). Interestingly, adverse
events were reported in three trials. However, the numbers of adverse
events were higher in the placebo groups than the D-amphetamine
groups, suggesting that the D-amphetamine may not be responsible for
generating an increase in adverse events (Harbeck-Seu et al., 2011).Concomitant medications and secondary medical interventions are prin-
cipal co-variables in stoke studies that are difﬁcult to control or evaluate
in trials of small size. The seven other trials did not list any adverse events
associated with D-amphetamine administration.
A second issuewith these trials involved the dosing regimen coupled
to physical training. Many of the trials administered D-amphetamine
once or twice a week in small doses as part of a physical rehabilitation
study that involved a small cohort of patients (mean = 21). Given the
wide range of ages and the varied sequelae associated with stroke, it
may be useful to perform a larger study in which treatment is initiated
during the acute injury phase and carried out through the rehabilitation
periodwith consistent rehabilitationmethods. Supporting this possibility,
Goldstein conducted an assessment of amphetamine trials in stroke and
concluded, “The variable and largely negative clinical trial results could be
attributable to design factors related to stroke location and extent, the dosing
and timing of the drug, and the type, intensity, and timing of physiotherapy.”
(Goldstein, 2009).4. Pharmacology
Methamphetamine has been approved as a therapeutic compound
by every world regulatory agency. As a consequence, we now have
decades of clinical information associated with methamphetamine as
the prescription oral drug product Desoxyn® [methamphetamine HCl
tablets, United States Pharmacopeia (USP)]. In this formulation, meth-
amphetamine is used as a secondary treatment for attention deﬁcit
hyperactivity disorder (ADHD) in children over the age of six and for
the short-termmanagement of exogenous obesity. Used in this context,
the FDAhas approved the administration ofmethamphetamine at doses
of up to 25 mg/day. In addition, up to 60 mg/day of methamphet-
amine has been used in the treatment of narcolepsy (Mitler et al.,
1993). At low-to-moderate doses (5–30 mg), methamphetamine-
induced responses include arousal, reduced fatigue, euphoria, acceler-
ated heart rate, elevated blood pressure, pupil dilation, increased tem-
perature, reduced appetite, behavioral disinhibition and short-term
improvements in cognition. At higher doses (≥30mg) neuropsycholog-
ical effects, such as anxiety can be observed (Cruickshank and Dyer,
2009). Previous studies indicate thatmethamphetamine toxicity occurs
when plasma levels reach a range of 200–5000 ng/ml (Cruickshank and
Dyer, 2009). To avoid toxicity, current FDA guidelines consider accept-
able dosing (for both adults and children) at 25 mg within a 24-hour
period. Based on this guideline, dosing an average seven-year-old
(weighing approximately 25 kg) at 1 mg/kg for 24 h would achieve
the FDA-approved oral dose limit. In pharmacokinetic studies conduct-
ed in our laboratory, rats receiving methamphetamine at 0.5 mg/kg/h
(infused over a period of 24 h) produced a steady-state concentration
of approximately 25 ng/ml. This plasma level produced signiﬁcant
improvements in cognition and functional behavior following severe TBI
in rats (Rau et al., 2012, 2014). In humans, the oral bioavailability of
methamphetamine is approximately 70% but increases to 100% following
intravenous (IV) delivery (Ares-Santos et al., 2013). In order to
achieve a comparable therapeutic plasma methamphetamine target
level of 25 ng/ml as observed in rats, a 70 kg adult would need a total
dose of 17.9 mg.
Thus, it appears that a target steady state concentration (Css) of
25 ng/ml and the doses required to achieve it are substantially less than
the current approved dosing for clinical application within the United
States. By comparison,methamphetamine concentrations are substantial-
ly higher in recreational abusers. Various pharmacokinetic studies have
demonstrated that methamphetamine levels in recreational abusers
(via various routes of administration) are commonly in excess of
those seen under recommended clinical guidelines (Cruickshank and
Dyer, 2009). Peak concentrations of approximately 100 ng/ml or greater
are routinely observed in drug abusers (Cruickshank and Dyer, 2009).
Self-administration of methamphetamine in drug abuse is typically
233T. Rau et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 64 (2016) 231–236through the repetitive oral doses of 100 to 150 mg (Cruickshank and
Dyer, 2009).
Distribution studies with methamphetamine indicate that the drug
is rapidly absorbed into the brain. Methamphetamine exhibits high
lipophilicity (due to themethyl group) that yields a high tissue to plasma
ratio (Cruickshank and Dyer, 2009). Recent studies utilizing MRI and PET
imaging techniques in human volunteers revealed an equilibration brain
to blood ratio of N8 (Volkow et al., 2010). These studies indicate an elim-
ination half-life for methamphetamine on the order of 9 to 13 h (Volkow
et al., 2010). Thus, methamphetamine has a unique ability to rapidly
penetrate into the brain with a high tissue partitioning and persist for
extended periods. These properties, when combined with its neuropro-
tective properties, impart unique characteristics making it potentially
useful for treating injuries such as TBI, where rapid and persistent
intervention is critical to clinical outcomes.5. The potential role of monoamines in neuroprotection
and neurotoxicity
Amphetamine and methamphetamine reverse the function of
vesicular monoamine transporters (VMAT) as well as the cell surface
transporters for dopamine (DAT), norepinephrine (NET) and serotonin
(SERT) (Cruickshank and Dyer, 2009). This results in a redistribution
of dopamine, norepinephrine and serotonin from intracellular stores
into the synaptic cleft. Thus, methamphetamine serves as an indirect
agonist for dopamine, norepinephrine and serotonin receptors. In addi-
tion,methamphetamine attenuates themetabolismof thesemonoamines
by inhibiting monoamine oxidase, which results in prolonged neuronal
signaling (Cadet et al., 2007; Krasnova and Cadet, 2009).
In an effort to further elucidate the effect of eachmonoamine,we used
an in vitro strokemodel to assess the effect of dopamine, norepinephrine
and serotonin in regard to neuroprotection and neurotoxicity. Using
organotypic, rat hippocampal slice cultures (RHSC) exposed to 60 min
of oxygen glucose deprivation (OGD), we performed a dose–response
study in which each monoamine, at various concentrations, was placed
into the media during the recovery phase (Rau et al., 2011). We utilized
propidium iodide as an indicator of cell death to assess potential neuro-
protection (Rau et al., 2011). In these studies, serotonin signiﬁcantly
reduced neuronal loss when added at concentrations of 10 nM–100 μM
(Fig. 1). Interestingly, when 1 mM serotonin was added to the OGD-
exposed cultures, therewas a signiﬁcant increase in neuronal death com-
pared to the untreated slices exposed to OGD. This ﬁnding suggests that
serotoninmay play a key role in methamphetamine-mediated neurotox-
icity associated with high dosing.
Norepinephrine induced signiﬁcant protection when added to slice
cultures at concentrations of 10–100 nM. However, at higher concentra-
tions of 100 μM or 1 mM no signiﬁcant neuroprotective effect was
observed. Unlike serotonin, the higher concentrations of norepineph-
rine did not produce an increase in neuronal death. While high dosesFig. 1. Monoamines induce a dose dependent neuroprotective response in an in vitro mode
deprivation (OGD) and either untreated (UTD) or exposed to graded concentrations (10 nM
measured based on propidium iodide staining of dead neurons. *p b 0.05; **p b 0.01; ***p b 0.0of serotonin and norepinephrine produced toxicity or failed to protect
cells respectively, the highest concentrations of dopamine produced
the most robust dose-dependent neuroprotection. Taken together,
these data suggest that methamphetamine may mediate neuroprotec-
tion, at least in part, through a dopamine-dependent signaling mecha-
nism(s). It further suggests that many of the previous studies that have
attributedmethamphetamine-mediated neuropathology to reactive oxy-
gen species (ROS) generatedvia excess dopaminemetabolismmaynot be
considering thepotential neuropathological effects of serotonin. In further
support of our ﬁndings, Hirata et al. (1995) demonstrated a serotonin
dependent increase in superoxide radicals following the administration
of a high dose of methamphetamine (10 mg/kg every 2 h for four injec-
tions). Conversely, a similar response was not observed with a lower
dose (5mg/kg every 2 h for four injections), further reiterating the poten-
tial dose-dependent difference between methamphetamine-mediated
neuroprotection and neurotoxicity (Hirata et al., 1995).6. The neuroprotective effects of dopamine
The potential role of dopamine in protection from excitotoxicitywas
suggested more than a decade ago when Lee et al. (2002) used rat
primary hippocampal neuronal cultures to demonstrate a direct interac-
tion between D1 dopamine and NMDA receptors. The authors showed
that dopamine activation of D1 receptors resulted in reduced Ca2+
permeability of NMDA receptors, the activation of phosphoinositol-3
kinase (PI3K) and improved cell survival (Lee et al., 2002). Three years
later, Zou et al. (2005) demonstrated that D2 dopamine receptors
indirectly interact with AMPA receptors. Dopaminemediated activation
of D2 receptors resulted in the internalization of AMPA receptors, which
also activated PI3K kinase signaling, the phosphorylation of protein
kinase B (AKT), an upregulation of Bcl-2 expression and a reduction in
apoptotic cell death (Zou et al., 2005). Conﬁrming these observations,
we recently reported that methamphetamine-mediated neuroprotection
was signiﬁcantly reduced in vitro with either D1 or D2 receptor antago-
nists (Rau et al., 2011). We also demonstrated that methamphetamine-
mediated neuroprotection was blocked by PI3K inhibitors. Furthermore,
we reported that methamphetamine-mediated PI3K activation results
in enhanced phosphorylation of AKT and cell survival (Rau et al., 2011).
In addition to our studies, Vaarmann et al. (2013) recently demonstrat-
ed that dopamine prevented delayed calcium dysregulation as a con-
sequence of glutamate-mediated excitotoxicity. This effect was again
dependent on the activation of D1 and D2 receptors and was enhanced
by the addition of a monoamine oxidase inhibitor (Vaarmann et al.,
2013).
While it is known that all three monoamines are affected by amphet-
amine andmethamphetamine, it appears that this class of stimulants has
the greatest impact on dopamine signaling. Amphetamine increases
dopamine in the synaptic cleft as well as blocking reuptake at the
dopamine transporter (DAT) (Miller, 2011). Amphetamine also affectsl of stroke. Rat hippocampal slice cultures were exposed to 60 min of oxygen/glucose
–1 mM) of serotonin, norepinephrine or dopamine. Relative ﬂuorescence intensity was
01. Statistical analysis was done as ANOVA with Tukey post-hoc analysis.
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phorylation through protein kinase A and C (Miller, 2011). This, in turn,
results in a reverse transporter function of DAT, allowing further efﬂux
of dopamine into the synaptic cleft (Miller, 2011).
The role of dopamine signaling in cognition is directly linked to the
striatum, a structure that is commonly damaged in both stroke and TBI.
PET neuroimaging studies in humans have demonstrated a critical role
for the striatum in cognitive performance (Marie et al., 1999). Patients
with Parkinson's disease assessed using 18F-dopa were found to have a
correlation between dopamine depletion and decreased neuropsycholog-
ical performance (Broussolle et al., 1999; Duchesne et al., 2002; Marie
et al., 1999). In further PET imaging studies, a correlation was found
between decreased striatal D2 receptor activity and poor performance
on tasks measuring executive function, attention, and working memory
(Backman et al., 1997). Supporting this ﬁnding is a recent study in
humans that examined the effect of amphetamines on cognitive ﬂexibil-
ity. The researchers in this study found that amphetamine adminis-
tration improved cognitive ﬂexibility and this effect was dependent
on dopamine activity within the thalamocorticostriatal network.
They also found that the cognitive effect of amphetamines was more
pronounced in individuals that had higher baseline levels of dopamine
receptors in the thalamus and cortex and greater striatal dopamine
release (Samanez-Larkin et al., 2013).
7. Dose dependent effects of amphetamine and methamphetamine
There is clear evidence that amphetamine andmethamphetamine in-
duce the release of dopamine throughmultiplemechanisms. Fleckenstein
et al. (2007) proposed the “exchange-diffusionmodel” in which amphet-
amines bind to the extracellular site onDAT and competewith extracellu-
lar dopamine. DAT transports dopamine in a bi-directional manner, and
intracellular concentrations of dopamine are higher under normal physi-
ological conditions (Fleckenstein et al., 2007). Thus, binding of amphet-
amines causes reverse transport of cytosolic dopamine outside of the
cell (Panenka et al., 2013). Fleckenstein et al. (2007) also proposed the
“weak base hypothesis,” which suggests that as weak bases, amphet-
amines can reduce the vesicular membrane pH gradient, compromising
VMAT-2 activity and reducing vesicular sequestration of dopamine. How-
ever, it has been suggested that high concentrations of amphetamine
(N100 μM) would be required to accomplish this effect (Schwartz et al.,
2006). More recently Siciliano et al. (2014) demonstrated that low
concentrations (10 nM) of amphetamine cause DAT-dependent dopa-
mine release. In contrast, the authors also showed that higher concentra-
tions of only 10 μM amphetamine induced dopamine release via a DAT-
independent mechanism. These data further support the idea that low
doses of amphetamines are insufﬁcient to disrupt vesicular sequestration
and act solely as inhibitors of DAT (Siciliano et al., 2014).
While both methamphetamine and amphetamine increase DAT-
mediated dopamine efﬂux, these compounds can exert quite different
effects on neurons. Using an in vitro expression system, Goodwin et al.
(2009) reported that methamphetamine released ﬁve times more
dopamine than amphetamine in a DAT dependentmanner. The authors
further demonstrated that methamphetamine induced the release of
twice as much Ca2+ from intracellular stores compared to amphet-
amine (Goodwin et al., 2009). Recently, Saha et al. (2014) demonstrated
that amphetamine and methamphetamine differentially affect DAT
activity and spontaneous ﬁring of dopaminergic neurons (Saha et al.,
2014). Using cultured midbrain dopaminergic neurons, the authors
presented evidence that methamphetamine was less effective at increas-
ing the spontaneous ﬁring of these neurons. When added at equal con-
centrations (1 μM), methamphetamine induced signiﬁcantly less inward
current than amphetamine (Saha et al., 2014). Interestingly, Saha et al.
(2014) further demonstrated that intracellular methamphetamine, but
not intracellular amphetamine, signiﬁcantly attenuated the increase in
dopaminergic neuron ﬁring following the addition of extracellular dopa-
mine. Importantly, these authors further demonstrated that while bothamphetamine and methamphetamine induced DAT-mediated inward
currents were equally Na+-dependant, they also demonstrated that am-
phetamine-induced DAT-mediated inward currents were preferentially
Cl−-dependent (Saha et al., 2014).
As previously discussed, clinically low doses of methamphetamine
have been used to enhance cognition and treat ADHD. Recently, Branch
and Beckstead (2012) demonstrated the bidirectional and concentration
dependent effect of methamphetamine on dopaminergic neuron activity.
Using mouse midbrain slices, these authors demonstrated that low con-
centrations (300nM)ofmethamphetaminenot only enhanceddopamine
neuron ﬁring through DAT-mediated conductance, but also enhanced the
amplitude of dopamine-mediated inhibitory post-synaptic currents
(IPSCs). In contrast, higher concentrations (10 μM) of methamphetamine
reversed both of these effects (Branch and Beckstead, 2012). Collectively,
these data provide further strong support for the concentration depen-
dent effects of methamphetamine on neuroprotection and neurotoxicity.
8. Impact of amphetamines on cognition and neurogenesis
While the clinical value of amphetamines in neuromotor rehabilita-
tion remains in question, there is evidence that suggests amphetamines
may enhance cognition and play a role in recovery of cognitive function
after acute brain injury.Walker-Batson et al. (1992) examined the poten-
tial of amphetamine treatment to improve aphasia in stroke patients.
Again, only a small number of patients were examined (6 patients
total). However, the authors reported that 5 out of 6 patients performed
better than expected on the Porch Index at six months post-stroke
(Walker-Batson et al., 1992).
Using a lowdose regimen (a single IV infusion of 0.5mg/kg/h for 24 h)
we observed a signiﬁcant enhancement in learning andmemory in unin-
jured (sham) rats when compared to uninjured saline treated rats (per-
formance was assessed 42 days after treatment) (Rau et al., 2012).
Using a different dosing regimen Moenk and Matuszewich (2012) also
reported that low dose methamphetamine produced a signiﬁcant and
long-term effect on cognitive behavior in uninjured rats. In their studies,
these authors administered once daily injections of 2 mg/kg for 15 days
to juvenile rats (post-natal day 20–34). Performance in the Morris
water maze was then assessed approximately 45 days after treatment.
Interestingly, under these dosing conditions, the signiﬁcant improvement
inMorris watermaze performancewas only observedwhen juvenile rats
were treated. Adult rats (post-natal day 70–84) treated with this same
dosing regimen did not exhibit signiﬁcant improvements in learning
(Moenk and Matuszewich, 2012).
TBI and stroke often impact the hippocampus, which is critical to
learning andmemory. Traditionally, the hippocampus has been studied
in terms of glutamate signaling. However, dopaminergic inputs play
a key role in the modulation of hippocampal function (Hansen and
Manahan-Vaughan, 2014). It has been demonstrated that dopamine
receptors in the hippocampus facilitate the maintenance of long-term
potentiation (LTP) through projections from the subthalamic nucleus
(Takahashi, 2013). This is a factor in cognitive performance as the facil-
itation of LTP in the hippocampus is a critical step in memory formation
and consolidation (Lemon and Manahan-Vaughan, 2006). There is also
evidence that dopamine receptor activation may spare neurons in the
hippocampus after TBI. Kline et al. (2004) administered bromocriptine,
a D2 receptor agonist, to rats 15 min prior to exposure to a TBI. Results
from this study concluded that bromocriptine administration resulted in
a signiﬁcant increase in CA3 neuronal survival aswell as reducedmemory
deﬁcits (Kline et al., 2004). Furthermore, our own studies revealed that
the administration of low dose methamphetamine signiﬁcantly pre-
served CA1 neurons following severe TBI (Rau et al., 2012, 2014).
We recently demonstrated that methamphetamine signiﬁcantly
enhanced learning and memory following TBI (Rau et al., 2012, 2014).
Supporting this ﬁnding, a second study demonstrated that increasing
dopamine release and blocking reuptake using amantadine signiﬁcantly


































Fig. 2.Methamphetamine treatment preservesmossy cells within the hippocampus hilar region.Mossy cells in parafﬁn embedded brain sectionswere stainedwith anti-GluR2/3 antibody
(red) and neuronswere stainedwith neurotrace (green). ***p b 0.001 relative to uninjured controls (shams). Scatter plot at right shows pairwise comparison betweenmossy cell numbers
and SST positive inhibitory interneuron numbers in uninjured controls (red dots), methamphetamine treated TBI rats (blue dots), and saline treated TBI rats (green dots).
235T. Rau et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 64 (2016) 231–236also showed that methamphetamine treatment signiﬁcantly enhanced
neurogenesis of granule neurons in the hippocampus following severe
TBI (Rau et al., 2012). Recent evidence indicates that mossy cells are
the ﬁrst glutamatergic neurons to make contact with newborn granule
neurons (Chancey et al., 2014). Mossy cells also provide considerable
feed forward inhibition onto granule neurons via parvalbumin (PV)
and somatostatin (SST) positive inhibitory interneurons. However,
mossy cells are also extremely vulnerable to injury and damage follow-
ing stroke or TBI (Chancey et al., 2014). The preservation of these cells as
well as PV or SST positive inhibitory interneurons is likely to have a
profound impact on granule neuron signaling and learning/memory.
Mossy cells receive considerable monoamine input (Harley, 2007;
Jinde et al., 2013). Based on these structural connections we attempted
to determine if methamphetamine treatment could preserve mossy
cells following severe TBI. We observed a signiﬁcant preservation of
mossy cells 48 h after TBI when low dose methamphetamine was
administered beginning 8 h after injury (Fig. 2). Furthermore, while
methamphetamine treatment had no effect on the preservation of PV
cells, we did observe a signiﬁcant reduction in SST inhibitory neuron
loss following TBI (Fig. 2).
9. Conclusion
There is clear evidence that methamphetamine, in high repetitive
doses, produces neuropathology. However, the characteristics andmech-
anisms thatmake it a highly addictive drugof abuse, also impart value as a
potential therapeutic intervention for acute brain injury. Methamphet-
amine crosses the blood brain barrier rapidly and in low doses produces
very few side effects. In the brain, methamphetamine potently increases
dopamine signaling throughout the cortex, striatum and hippocampus.
Furthermore, methamphetamine has a relatively long half-life in humans
and thus high concentrations are not necessary to achieve a therapeutic
effect. Also, methamphetamine is metabolized to amphetamine, which
further prolongs the active effects in the brain.
In all of our studies using low dosemethamphetamine we have not
found any evidence of neuropathology caused by the drug treatment.
To the contrary, we have observed a reduction in neuronal loss,apoptotic cell death, and neuromotor/cognitive impairment after
acute brain injury. In light of the fact that low dose methamphetamine
is FDA approved for use in juveniles and adults, we see no valid reason
why it cannot be utilized in human clinical trials for stroke and TBI. We
propose that low dose methamphetamine has signiﬁcant potential as a
neuroprotective agent when the dosing is kept within safe, previously
established guidelines.
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